Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
We hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.
Description: Time to improvement in oxygenation
Measure: Time to improvement in oxygenation Time: 28 DaysDescription: 28-day mortality
Measure: 28-day mortality Time: 28 DaysDescription: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy
Measure: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy Time: 28 DaysDescription: Qualitative and quantitative toxicity
Measure: Qualitative and quantitative toxicity Time: 28 DaysDescription: incidence and duration of supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device
Measure: incidence and duration of supplemental oxygen administration Time: 28 DaysDescription: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula
Measure: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula Time: 28 DaysDescription: Incidence and duration of mechanical ventilation
Measure: Incidence and duration of mechanical ventilation Time: 28 DaysDescription: Incidence and duration of vasopressor support
Measure: Incidence and duration of vasopressor support Time: 28 DaysDescription: Incidence and duration of extracorporeal membrane oxygenation
Measure: Incidence and duration of extracorporeal membrane oxygenation Time: 28 DaysDescription: Duration of fever
Measure: Duration of fever Time: 28 DaysDescription: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives
Measure: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives Time: 28 DaysDescription: Duration of hospitalization
Measure: Duration of hospitalization Time: 28 DaysDescription: Secondary infections
Measure: Secondary infections Time: 28 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports